Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company's current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology.

Liquidia Corporation

Liquidia Corporation | 7,350 followers on LinkedIn. A biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease.  | Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. Liquidia has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia is also developing L606, an investigational liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer, for use in North America.

Chief Operating Officer at OA Private Capital (“OAPC”) / RDV Affiliate

Damian deGoa

I elevate healthcare leaders, brands, products and initiatives using smart communications strategies that make a measurable impact.

Patrick Wallace

Providing GxP Compliance Expertise and Leadership

David Dumers

Kristan Amicone

Liquidia Corporation (NASDAQ: LQDA) announced today it will report its third quarter 2024 financial results on November 13, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and to provide a corporate update. Click here for more information: https://bit.ly/3NUfe8j

At Liquidia, we’re proud to support Pulmonary Hypertension Awareness Month throughout the month of November. Join us in our efforts to raise awareness about pulmonary hypertension and learn how members of the PH community are letting their light shine. Visit the Pulmonary Hypertension Association here for more information: https://bit.ly/2IfiVXh #PHAwarenessMonth #LetYourLightShine

Did you know that #PHILD can lead to increased pulmonary vascular resistance and right heart failure? This condition complicates ILD, making early diagnosis and advanced therapies crucial for improving patient outcomes. At Liquidia, we're working to develop novel treatments for #PAH and PH-ILD patients in need. Learn more about our work here: https://bit.ly/3zpBPWt

It truly takes a team to accomplish fetes such as these! Congratulations to Team PHenomenal Hope ( #TeamPH ), its #LetMeBeYourLungs team and Liquidia’s very own Jessica Ashbaucher . Together, they took on the arduous task of climbing to #MountEverest Base Camp to help raise awareness and critical research funds for the benefit of the #pulmonaryhypertension community. On behalf of all of us at Liquidia, we salute you!

The Liquidia team consists of industry-leading scientists, clinicians, business strategists, engineers, & pharmaceutical executives, working together to help people lead longer, healthier, and happier lives. By combining our diverse expertise, we’re pushing the boundaries of innovation in healthcare, working to develop solutions that make a real difference in patients' lives. Learn more: https://lnkd.in/ga5DV4xd

Today we announced that the U.S. Supreme Court has rejected a request to appeal prior decisions around a patent for a competing product. Our CEO, Roger Jeffs said, "We are pleased that the Supreme Court has denied the petition by United Therapeutics and affirmed previous rulings that every claim of the ‘793 patent is invalid. We are grateful that this specific chapter has come to a close and that the ‘793 patent will now be forever unenforceable. We will continue to fight for the earliest possible launch of YUTREPIA so that patients and physicians have access to the unique benefits that YUTREPIA can provide." Read more in our press release: https://bit.ly/4eTtR75

October is #HealthyLungMonth , a reminder to take care of the organs that power every breath. At Liquidia, we're committed to advancing innovative treatments for those facing rare cardiopulmonary diseases like #PAH and #PHILD . Check out these tips from American Lung Association for keeping your lungs healthy: https://bit.ly/4gQaayQ

Today we announced an expanded collaboration with Pharmosa Biopharm Inc (Pharmosa) for the development and commercialization of L606, an investigational, inhaled, sustained-release formulation of #treprostinil currently being evaluated in a clinical trial for the treatment of pulmonary arterial hypertension ( #PAH ) and pulmonary hypertension associated with interstitial lung disease ( #PHILD ). For more information, see today’s press release: https://bit.ly/47SOq1b

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

COM:LIQUIDIA

Liquidia Corporation

Last Close

10.15

22/11 21:00

Market Cap

955.17M

Beta: -

Volume Today

1.05M

Avg: -

Analysis Not Available